VRTX (Vertex Pharmaceuticals Incorporated) Stock Financials & Earnings

VRTXVertex Pharmaceuticals Incorporated

Mkt Cap$129B

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Revenue (TTM)$12.0B

Net Income (TTM)$4.0B

EPS (TTM)$15.33

Free Cash Flow (TTM)$3.2B

Gross Margin86.3%

Op. Margin35.5%

Net Margin32.8%

FCF Margin26.5%

P/S Ratio (TTM)10.7x

P/E Ratio (TTM)32.5x

YoY Rev Growth+9.3%

Employees—

Earnings Reports

Revenue & Profitability

Quarter	Revenue	Gross Profit	Op. Income
Q1 23	$2.4B	$2.1B	$779M
Q2 23	$2.5B	$2.2B	$1.0B
Q3 23	$2.5B	$2.2B	$1.0B
Q4 23	$2.5B	$2.1B	$989M
Q1 24	$2.7B	$2.3B	$1.1B
Q2 24	$2.6B	$2.3B	-$3.5B
Q3 24	$2.8B	$2.4B	$1.1B
Q4 24	$2.9B	$2.5B	$1.0B
Q1 25	$2.8B	$2.4B	$630M
Q2 25	$3.0B	$2.6B	$1.2B
Q3 25	$3.1B	$2.7B	$1.2B
Q4 25	$3.2B	$2.8B	$1.3B

Revenue Breakdown

Valuation

Operating Cash Flow

Capital Expenditures

CapEx

OpEx vs Revenue Growth (YoY)

Stock-Based Compensation

OpEx Breakdown

Revenue Segments

Quarter	Kalydeco	Orkambi	Symdeko/Symkevi	Trikafta/Kaftrio	Manufactured Product, Other	Alyftrek
Q1 23	$125M	$123M	$31M	$2.1B	—	—
Q2 23	$125M	$96M	$31M	$2.2B	—	—
Q3 23	$113M	$63M	$33M	$2.3B	—	—
Q4 23	$112M	$44M	$28M	$2.3B	—	—
Q3 24	—	—	—	$2.6B	$187M	—
Q1 25	—	—	—	$2.5B	$171M	$54M
Q2 25	—	—	—	$2.6B	$236M	$157M
Q3 25	—	—	—	$2.7B	$176M	$247M
Q4 25	—	—	—	$2.6B	$237M	$380M

Revenue by Geography

Quarter	Europe	Other, Non U.S.	United States
Q1 23	$807M	$164M	$1.4B
Q2 23	$800M	$185M	$1.5B
Q3 23	$767M	$163M	$1.6B
Q4 23	$735M	$208M	$1.6B
Q1 24	$967M	$203M	$1.5B
Q2 24	$807M	$225M	$1.6B
Q3 24	$848M	$211M	$1.7B
Q4 24	$832M	$243M	$1.8B
Q1 25	$827M	$280M	$1.7B
Q2 25	$911M	$206M	$1.8B

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 23	$9.3B	$1.1B	$10.4B
Q2 23	$10.2B	$1.1B	$11.2B
Q3 23	$11.1B	$818M	$11.9B
Q4 23	$10.4B	$849M	$11.2B
Q1 24	$9.2B	$1.0B	$10.2B
Q2 24	$4.6B	$1.2B	$5.8B
Q3 24	$5.2B	$1.3B	$6.5B
Q4 24	$4.6B	$1.5B	$6.1B
Q1 25	$4.7B	$1.5B	$6.2B
Q2 25	$5.0B	$1.4B	$6.4B
Q3 25	$4.9B	$1.3B	$6.3B
Q4 25	$5.1B	$1.5B	$6.6B

Shares Outstanding

Revenue Per Employee

Revenue / Employee